Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired bySangamo BioSciences
Date8/2013
TermsStock

General Information

Offices

San Diego, USA
9381 Judicial Dr.
Ste. 130
San Diego, CA, 92121
USA

People

Co-Founder & Chairman
Board of Directors
Senior Research Associate

Funding

TOTAL $39.5M
FUNDING TOTAL $39.5M
Series C, 6/2007
Investor Growth Capital
Alta Partners
California Technology Ventures
Hamilton BioVentures
MPM Capital
Cell Genesys
$28M
Series D, 11/2010
$11.5M

Tags

Ceregene

Ceregene is a private, San Diego-based biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Their clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor, which is about to enter Phase 2 studies for the treatment of Alzheimer’s disease, and CERE-120, which recently completed a Phase 2 trial in Parkinson’s disease and is currently being evaluated for future development. CERE-135 and CERE-140 are in preclinical development for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and ocular diseases, respectively.

Recent Milestones

Videos

Screenshots

Ceregene screenshot
Above: Ceregene
Uploaded: 3/11/10

Sources

  1. Sangamo BioSciences to Acquire Gene-Therapy Co. Ceregene (pevc.dowjones.com) [edit]
  2. Ceregene Partners With Genzyme, Inks $28M Series C (altapartners.com) [edit]
  3. VCs inject $29M into Syntaxin, $11.5M into Ceregene (fiercebiotech.com) [edit]
Edit This Page
Last Edited 11/25/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy